Indication intelligence, analysis and sector perception

Muted open expected; RMi’s analysis, riding out a spasmodic month

May 26, 2016 6:41am

The absence of investor enthusiasm spells a trading set-up

Indexes and ETFs: the IBB, XBI and IWM are UP and the XLV is down

Investing actions: JUNO and OPXA

I say today what others won't, so you can do what others can't; whether information or intelligence is good, bad or somewhere in between – it defines the who, when, where, which and what of it …

Where are today’s markets going?

Dow futures are UP +0.11% and NASDAQ futures are UP +0.12%

U.S. stock index futures were broadly higher on Thursday morning as traders looked to the release of several pieces of data and earnings.

European stocks seesawed between positive and negative territory amid a rebound in oil prices.

Asian markets were mixed as the energy sector saw gains as oil prices hit the $50-a-barrel mark for the first time since early November.

Data docket: initial claims and durable goods orders are set to be released at 8:30 a.m. ET, while pending home sales are due to come out at 10:00 a.m.

The stem, cell and gene therapy regenerative medicine (SCGT&RM) sector closed POSITIVE on Wednesday, Tuesday, Monday and Friday and NEGATIVE on last Thursday.

The stem, cell and gene therapy regenerative medicine sector’s record after the last 5 days (of 43 covered companies):

Wednesday closed POSITIVE with 15 decliners, 27 advancers and 1 flat;
Tuesday closed POSITIVE with 10 decliners, 29 advancers and 4 flats;
Monday closed POSITIVE with 12 decliners, 26 advancers and 5 flats;
Friday closed POSITIVE with 10 decliners, 31 advancers and 2 flats;
Last, Thursday closed NEGATIVE with 35 decliners, 5 advancers and 3 flats;

Remembering Wednesday’s post, “Today seemed to “roll” against expectation of a down session after three positive days as traders probably did NOT see enough of a gain in sector stocks to take them down!”

Incrmenemntally, we have seen few big swings and some of those are being depleted but, the sector has been UP for four days in a row ! There are still many nagging doubts agout the sustainability of “our” universe

The tired and sluggish sector from thes four days and last week has everyone pretty much on the edge – waiting for the next downside.

The problem is, we need the traders and speculators or we wouldn’t have a market –investors have kept walking!

You’ve made it to the office, turned on the monitor, having just gotten your coffee and it hits you - what could be today’s trades?

There has been a tempering of the risk appetite at the sector “table” that has driven smaller upsides <except in a few cases> in recent days. Sentiment is looking somewhat weak and tired mixedforecasting more downside moves.

Watch list:

The iShares Nasdaq Biotechnology (IBB) closed Wednesday up +1.10% and is DOWN -0.01% in Thursday’s pre-market;
The SPDR S&P Biotech ETF (XBI) closed Wednesday up +1.63% and is DOWN -0.04% in Thursday’s pre-market;
NASDAQ Biotechnology (NBI) closed up Wedneesday +1.15%;
The Health Care Select Sector SPDR ETF (XLV) closed up Wednesday +0.62% and is UP +0.14% in Thursday’s pre-market;
The iShares Russell 2000 (IWM) closed Wednesday up +0.58% and is UP +0.03% in Thursday’s pre-market.

Companies in the spotlight;

Juno Therapeutics (JUNO) closed DOWN -$0.10 to $40.28 after Tuesday’s +$0.19. UP, down, round and round share pricing fluctuates. Technical indicators are mixed, JUNO‘s change in share price of -11.16% for the last 12 months is better than its peer median. However, the 30-day trend in its share price performance of -4.90% is now around the peer median suggesting that JUNO’s recent performance has faded relative to peers – Maintaining SELL;

Opexa (OPXA) closed UP +$0.21 to $3.29 after Tuesday’s +$0.43. Watch for the “skim” of the upside as 5/19’s <Thursday> pricing was $2.09. Strength in micro-caps is to be sold into – Maintaining SELL;

Opinions expressed are those of the author and are subject to change, and are not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.